| Inhibition of breast cancer cell survival by Xanthohumol via modulation of the Notch signaling pathway in vivo and in vitro Z Sun, C Zhou, F Liu, W Zhang, J Chen, Y Pan, L Ma, Q Liu, Y Du, J Yang, ... Oncology letters 15 (1), 908-916, 2018 | 65 | 2018 |
| Etoposide, an anticancer drug involved in therapy-related secondary leukemia: Enzymes at play W Zhang, P Gou, JM Dupret, C Chomienne, F Rodrigues-Lima Translational oncology 14 (10), 101169, 2021 | 63 | 2021 |
| Human protein tyrosine phosphatase 1B (PTP1B): from structure to clinical inhibitor perspectives R Liu, C Mathieu, J Berthelet, W Zhang, JM Dupret, F Rodrigues Lima International Journal of Molecular Sciences 23 (13), 7027, 2022 | 59 | 2022 |
| Effect of xanthohumol on Th1/Th2 balance in a breast cancer mouse model W Zhang, Y Pan, P Gou, C Zhou, L Ma, Q Liu, Y Du, J Yang, Q Wang Oncology reports 39 (1), 280-288, 2018 | 50 | 2018 |
| Insights into the potential mechanisms of JAK2V617F somatic mutation contributing distinct phenotypes in myeloproliferative neoplasms P Gou, W Zhang, S Giraudier International Journal of Molecular Sciences 23 (3), 1013, 2022 | 14 | 2022 |
| Human CREBBP acetyltransferase is impaired by etoposide quinone, an oxidative and leukemogenic metabolite of the anticancer drug etoposide through modification of redox … W Zhang, J Berthelet, C Michail, LC Bui, P Gou, R Liu, R Duval, J Renault, ... Free Radical Biology and Medicine 162, 27-37, 2021 | 11 | 2021 |
| T-cell protein tyrosine phosphatase is irreversibly inhibited by etoposide-quinone, a reactive metabolite of the chemotherapy drug etoposide Q Nian, J Berthelet, W Zhang, LC Bui, R Liu, X Xu, R Duval, S Ganesan, ... Molecular pharmacology 96 (2), 297-306, 2019 | 11 | 2019 |
| N6-substituted adenosine analogues, a novel class of JAK2 inhibitors, potently block STAT3 signaling in human cancer cells P Liu, L Zhao, X Xu, F Liu, W Zhang, C Zhou, J Chen, Y Pan, Y Du, J Yang, ... Cancer Letters 354 (1), 43-57, 2014 | 7 | 2014 |
| SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions Q Deng, P Lakra, P Gou, H Yang, C Meydan, M Teater, C Chin, W Zhang, ... Cancer cell 42 (4), 605-622. e11, 2024 | 3 | 2024 |
| A readout of metabolic efficiency in arylamine N‐acetyltransferase‐deficient mice reveals minor energy metabolism changes RGP Denis, F Busi, J Castel, C Morel, W Zhang, LC Bui, KS Sugamori, ... FEBS letters 593 (8), 831-841, 2019 | 3 | 2019 |
| Cisplatin causes covalent inhibition of protein-tyrosine phosphatase 1B (PTP1B) through reaction with its active site cysteine: Molecular, cellular and in vivo mice studies R Liu, W Zhang, P Gou, J Berthelet, Q Nian, G Chevreux, V Legros, ... Biomedicine & Pharmacotherapy 153, 113372, 2022 | 2 | 2022 |
| Protein lysine acetyltransferase CBP/p300: A promising target for small molecules in cancer treatment P Gou, W Zhang Biomedicine & Pharmacotherapy 171, 116130, 2024 | 1 | 2024 |
| Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasms P Gou, D Liu, S Ganesan, E Lauret, N Maslah, V Parietti, W Zhang, ... Blood Cancer Journal 14 (1), 1, 2024 | 1 | 2024 |
| CREBBP lysine acetyltransferase domain mutations create zombie enzymes that alter chromatin loading dynamics and prevent EP300 redundancy H Yang, W Zhang, V Ravanmehr, A Mechaly, L Regad, A Haouz, R Chen, ... bioRxiv, 2023.09. 05.556242, 2023 | | 2023 |
| From transglutaminases (TGs) to arylamine N-acetyltransferases (NATs): Insight into the role of a spatially conserved aromatic amino acid position in the active site of these … X Xu, W Zhang, J Berthelet, R Liu, C Michail, AF Chaffotte, JM Dupret, ... Biochemical and Biophysical Research Communications 525 (2), 308-312, 2020 | | 2020 |
| Trisubstituted Hexahydroimidazo [1, 2-α] Pyridine 6 (TIP-6) as a Small-Molecule Inhibitor of Bcl-2 for Inhibition of Proliferation in Hepatoma Cells W Zhang, Y Pan, H Zhou, X Gao, J Song, Y Hua, Y Du, J Yang, X Hui, ... Journal of Biosciences and Medicines 7 (1), 29-41, 2018 | | 2018 |
